Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Denver, Colorado Clear all
Completed Phase 4 Interventional Results available

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

NCT00118742
View directory record Official record
Conditions
Liver Transplantation
Interventions
mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01720069
View directory record Official record
Conditions
Asthma
Interventions
VR506
Drug
Lead sponsor
Vectura Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Celebration, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 25, 2026, 9:14 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Skin Characteristics of Parents of Food Allergic Pediatric Patients

NCT04198753
View directory record Official record
Conditions
Food Allergy in Children
Interventions
Skin tape stripping, Skin barrier assessment, Blood draw
Diagnostic Test · Device
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
141
States / cities
Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

NCT02451137
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
407
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Not applicable Interventional

A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

NCT06676072
View directory record Official record
Conditions
Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
Interventions
PFA Ablation catheter
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

NCT01150045
View directory record Official record
Conditions
Colorectal Cancer
Interventions
celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
826
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, oral placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Bexagliflozin Efficacy and Safety Trial

NCT02558296
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
40 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
66
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00313586
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions
Azacitidine, Entinostat, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
234
States / cities
Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

NCT01168973
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo (for Ramucirumab), Docetaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
97
States / cities
Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Warmed Irrigation in Hip Arthroscopy Undergoing Hip Arthroscopy

NCT03453866
View directory record Official record
Conditions
Femoro Acetabular Impingement, Pain, Postoperative
Interventions
Warmed Arthroscopic Fluids, Room Temperature Arthroscopic Fluids
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 25, 2026, 9:14 AM EDT
Completed No phase listed Observational

Examining Heart Attacks in Young Women

NCT00597922
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
2,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • La Mesa, California + 76 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 25, 2026, 9:14 AM EDT
Completed No phase listed Observational

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

NCT02728934
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 25, 2026, 9:14 AM EDT
Completed No phase listed Observational

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

NCT00001121
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Results available

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

NCT03329001
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib Tablet, Niraparib Capsule
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jul 25, 2026, 9:14 AM EDT
Active, not recruiting Not applicable Interventional

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

NCT03499236
View directory record Official record
Conditions
Heart Failure
Interventions
V-Wave Interatrial Shunt, Control
Device · Other
Lead sponsor
V-Wave Ltd
Industry
Eligibility
18 Years to 99 Years
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 25, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

A Multicenter Study to Evaluate Functional Outcome After Knee Replacement

NCT02494544
View directory record Official record
Conditions
Osteoarthritis
Interventions
Off the Shelf Total Knee Replacement, ConforMIS iTotal Knee Replacement
Device
Lead sponsor
Restor3D
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
La Jolla, California • San Diego, California • Parker, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 25, 2026, 9:14 AM EDT
Recruiting Phase 3 Interventional

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00391807
View directory record Official record
Conditions
Contraception
Interventions
Norethindrone acetate/ethinyl estradiol
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
66
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 25, 2026, 9:14 AM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Jul 25, 2026, 9:14 AM EDT
Completed Not applicable Interventional

Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures

NCT02295098
View directory record Official record
Conditions
Rib Fractures, Wounds and Injuries
Interventions
Thoracic epidural catheter placement, Paracostal catheter placement
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 25, 2026, 9:14 AM EDT